ClinicalTrials.gg
CompletedNCT02606357NEWLANUpdated Oct 12, 2018

Treatment of Type 2 Diabetes With Long Acting Basal Insulin in Jordan

A Phase 4 interventional study of INSULIN GLARGINE in Diabetes Mellitus, Type 2, sponsored by Sanofi. Completed at 1 site in Jordan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-12.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
242
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 — 4 open to participants now, 6 under way, 1 of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 2.

Enrollment
92nd of 175
242 · median 253
Started
2015
with 13 others
Phase 4
103 of 176
2 open now
Registered
129th of 176
by date
Lead sponsor
82 of 176
Sanofi

Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, this one is the 92nd largest by enrollment of the 175 interventional ones that give a count, is one of 14 that started in 2015, is one of 103 in phase 4, and was the 129th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About Insulin Glargine

Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Primary Objective:

-To assess the change in glycosylated hemoglobin (HbA1c) in uncontrolled Type 2 diabetes patients on OAD agent in Jordan after 6 months of treatment with basal insulin (Insulin glargine).

Secondary Objectives:

  • To evaluate the percentage of patients achieving target of HbA1c ˂7%.
  • To evaluate the change in fasting plasma glucose (FPG).
  • To assess the following safety criteria: hypoglycemic events, body weight changes, and overall safety.
  • Describe the titration process: changes in glargine insulin dose at 3 months and 6 months, changes in the titration doses used (if any), and time to reach control.
Read the detailed description

The total duration of study period per patient is up to 6 months.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient ≥ 18 years old.
  • Male or Female.
  • Type 2 diabetes patients.
  • Uncontrolled with previous therapy ( >7%), evident in HbA1c test within the last 1 month before study entry.
  • Insulin naïve patients: any patient uncontrolled after one or a maximum of two including: monotherapy (Metformin alone or any other Oral Anti-Diabetic agent (OAD) if or intolerance) and/or dual therapy (any OAD combination), at maximum tolerated dose in the last 3 months.
  • Signed .
  • Signed informed consent.

Exclusion criteria

Exclusion criteria:

  • Patient not willing or not able to perform self-monitoring blood glucose.
  • Patient not willing or not able to self-titrate insulin glargine under physician's guidance.
  • Patient not suitable for participation according to what is specified in the approved Summary of Product's Characteristics or according to medical or clinical conditions, as judged by the Investigator.
  • History of impaired hepatic function defined as (ALT) and/or aspartate aminotransferase (AST) greater than three times the , evident in testing done in the last 3 months.
  • History of impaired renal function defined as serum creatinine >135 μmol/L (>1.525 mg/dL)in men and >110 μmol/L (>1.243 mg/dL) in women, evident in testing done in the last 3 months.
  • Pregnant or lactating women (women of must have a negative pregnancy test at study entry and a medically approved method at physician's discretion).
  • Treatment with systemic within 3 months prior to study entry.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
242 participants (actual)

Study arms

  • Experimental
    HOE901

    HOE901 administered subcutaneously once a day in the evening, at dinner, or at bedtime with titration based on FPG levels

    Drug: INSULIN GLARGINE

Interventions

  • Pharmaceutical form:Solution Route of administration: Subcutaneous

    Also known as: HOE901

06

What researchers measure

Primary outcomes

  1. Change from baseline in HbA1c

    Time frame: Baseline, 6 months

Secondary outcomes

  1. - Percentage of patients achieving target of HbA1c <7%

    Time frame: 6 months

  2. - Change from baseline in fasting plasma glucose values

    Time frame: Baseline, 3 months, and 6 months

  3. - Percentage of patients with hypoglycemic events

    Time frame: Baseline, 6 months

  4. - Change from baseline in body weight

    Time frame: Baseline, 3 months and 6 months

  5. - Number of patients with adverse events

    Time frame: Baseline, 6 months

  6. - Change in dose of insulin glargine

    Time frame: 3 months and 6 months

  7. - Change in the titration doses used (if any)

    Time frame: 6 months

  8. - Time to reach control

    Time frame: 6 months

07

Study locations

1 site
  • JORDAN
    Jordan, Jordan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2015 to primary completion in Nov 2017, 24 months.

Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 24 months is above that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2015
First posted
Nov 17, 2015
StartActual
Nov 22, 2015
Primary completionActual
Nov 27, 2017
CompletionActual
Nov 27, 2017
Last update
Oct 12, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 12, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02606357
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Nov 17, 2015
Start date
Nov 22, 2015
Primary completion
Nov 27, 2017
Completion
Nov 27, 2017
Last update
Oct 12, 2018

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Glargine

Start the discussion